Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2001
10/10/2001EP1140001A2 Composition for treatment of burns
10/10/2001EP1140000A1 Osmetische oder dermatologische zusammensetzub
10/10/2001EP1139996A1 Deodorizing cosmetic agents
10/10/2001EP1139974A1 Soy depigmenting and skin care compositions
10/10/2001EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
10/10/2001EP1139781A1 Food or veterinary composition for domestic carnivores containing free tyrosine
10/10/2001EP0840620B1 Il-8 antagonists for treatment of asthma
10/10/2001EP0793476B1 Use of Mangiferin or Derivatives thereof for Cosmetic Applications
10/10/2001CN1317047A GBS toxin receptor
10/10/2001CN1317045A Pharmaceutical uses of NAB1 and NAB2
10/10/2001CN1317043A Polypeptides and polynucleotides from coagulase-negative staphylocoui
10/10/2001CN1316995A Hydroxy 2-pipecolate hydroxamide acid derivatives as MMP inhititors
10/10/2001CN1316993A 4,4-biarylpiperidime derivatives with opioid receptor activity
10/10/2001CN1316905A Composition for stimulation melanin synthetic and preparing method thereof
10/10/2001CN1316419A Arenesulfonyl amino-iso hydroximic acid derivative
10/10/2001CN1316272A Medicinal preparation for reducing hair growth, hair follicle and hair shaft dimension and hair pigmentation
10/10/2001CN1316268A Qufengbaidu pill for treating skin itchings
10/10/2001CN1316252A Exterior-applied medicine for treating acne and its preparing process
10/10/2001CN1072664C Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compound
10/10/2001CN1072499C External-use medicine for curing body surface chronic ulcers
10/10/2001CN1072498C External-use medicine for treating burn and scald of humanbody
10/10/2001CN1072496C Haisong injury paste
10/10/2001CA2343426A1 Compound, specificially for cosmetic use, containing a steroid and a 2-alkyl acanol or an ester
10/09/2001US6300374 Applying the medicament comprising zinc salt of conjugated linoleic acid to a skin disorder, wherein the skin disorder is skin cancer
10/09/2001US6300345 Cyanoguanidines as cell proliferation inhibitors
10/09/2001US6300341 2-substituted heterocyclic sulfonamides
10/09/2001US6300334 Thieno[2,3-d]pyrimidine-2,4-diones
10/09/2001US6300325 Heterocyclic receptor antagonist
10/09/2001US6299888 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation
10/09/2001US6299885 External preparations containing watercress extract
10/09/2001CA2193224C Chinese herbs extract
10/07/2001CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/04/2001WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer
10/04/2001WO2001073033A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains
10/04/2001WO2001073025A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
10/04/2001WO2001073020A1 Materials and methods relating to a novel splice variant of a na+ dependent glutamate transporter
10/04/2001WO2001072970A2 Methods to prepare and use epidermal stem cells
10/04/2001WO2001072960A2 Il-8 receptor antagonists
10/04/2001WO2001072836A2 G-protein coupled receptors
10/04/2001WO2001072830A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
10/04/2001WO2001072829A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
10/04/2001WO2001072778A2 Method of identifying inhibitors of tie-2
10/04/2001WO2001072777A2 Human transcription factors
10/04/2001WO2001072767A1 Dehydroepiandrosterone derivatives, preparation method and uses thereof, in particular for cosmetics
10/04/2001WO2001072762A1 Pharmaceutical compositions containing oligosaccharides and preparation thereof
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072745A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
10/04/2001WO2001072744A1 N-heterocyclic derivatives as nos inhibitors
10/04/2001WO2001072737A1 Triarylimidazole derivatives as cytokine inhibitors
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072727A1 Hair tonics
10/04/2001WO2001072723A1 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/04/2001WO2001072720A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases
10/04/2001WO2001072717A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
10/04/2001WO2001072711A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072692A1 Malonamic acids and derivatives thereof as thyroid receptor ligands
10/04/2001WO2001072680A1 Substituted chalcones as therapeutic compounds
10/04/2001WO2001072678A1 Phenol derivatives, process for preparation of the same and use thereof
10/04/2001WO2001072347A1 Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin
10/04/2001WO2001072328A2 Methods of treating diseases with activated protein c
10/04/2001WO2001072325A1 Methods of blocking tissue destruction by autoreactive t cells
10/04/2001WO2001072315A1 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
10/04/2001WO2001072310A1 Pharmaceutical gel composition
10/04/2001WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease
10/04/2001WO2001072291A2 Treatment of movement disorders with metabotropic glutamate receptor antagonist
10/04/2001WO2001072287A2 Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression
10/04/2001WO2001072281A2 Microspheres for active embolization
10/04/2001WO2001072268A1 Hair growth or hair formation controlling agents
10/04/2001WO2001072265A1 External preparation for the skin and beautifying agents
10/04/2001WO2001072262A2 New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same
10/04/2001WO2001043704A8 A skin care composition that mediates cell to cell communication
10/04/2001WO2001023563A3 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
10/04/2001WO2001022959A3 Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions
10/04/2001WO2001021784A3 Pcna-associated cell cycle proteins, compositions and methods of use
10/04/2001WO2001019828A3 Kinase inhibitors as therapeutic agents
10/04/2001WO2001016319A3 Compositions and methods for the treatment of immune related diseases
10/04/2001WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
10/04/2001WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
10/04/2001WO2000032634A9 Humanized antibodies to gamma-interferon
10/04/2001US20010027213 Use of pyrethroid compounds to promote hair growth
10/04/2001US20010027211 Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents
10/04/2001US20010027207 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation; anticarcinogenic, -diabetic, -proliferative and -inflammatory agents; vascular system disorders
10/04/2001US20010027197 Antiproliverative, -carcinogenic and -tumor agents; mitogenesis-activated protein kinase inhibitors; noncytotoxic; binding with high affinity at the adenosine triphosphate binding site of the kinases
10/04/2001US20010026810 Polyurethane prepolymer with polyoxyethylene, polyoxypropylene or propylene glycol; absorbtive, contours to wound site; maintains moisture for healing; may contain fungicidal, bactericidal and deodorizing additives
10/04/2001US20010026794 Two heterologous DNA encoding gene products; prolonged half-life
10/04/2001EP1138680A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
10/04/2001EP1138329A2 Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions
10/04/2001EP1138314A2 Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues
10/04/2001EP1137766A1 Animal model for psoriasis for the prevention and treatment of psoriasis in humans
10/04/2001EP1137671A1 Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
10/04/2001EP1137661A1 Procollagen c-proteinase inhibitors
10/04/2001EP1137658A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
10/04/2001EP1137656A1 31 human secreted proteins
10/04/2001EP1137621A1 Aldose reductase inhibitors and pharmaceutical compositions
10/04/2001EP1137446A1 Collagen hemostatic foam
10/04/2001EP1137440A1 A stable product of isohexylnaphthazarins with penta- and tetra-cyclic triterpenes
10/04/2001EP1137438A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
10/04/2001EP1137415A1 Myt1 kinase inhibitors
1 ... 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 ... 1065